Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Apr 13, 2004
Hemispherx Biopharma to Present First Phase 3 Data on Ampligen in Chronic Fatigue Syndrome at the 17th International Conference on Antiviral Research
Mar 18, 2004
Hemispherx Biopharma Completes Acquisition for Worldwide Rights to Alferon N
Mar 15, 2004
HEMISPHERX BIOPHARMA REPORTS 2003 YEAR-END RESULTS
Mar 02, 2004
HEMISPHERX BIOPHARMA ANNOUNCES FDA AUTHORIZATION FOR A CLINICAL STUDY WITH NEW BIOLOGICAL ALFERON LDO FOR HIV
Feb 25, 2004
HEMISPHERX BIOPHARMA TO PRESENT AT WALL STREET ANALYST FORUM ON MARCH 1st
Feb 18, 2004
HEMISPHERX BIOPHARMA SIGNS OPTION AGREEMENT FOR AMPLIGEN WITH FUJISAWA PHARMACEUTICAL COMPANY
Jan 30, 2004
HEMISPHERX BIOPHARMA FINISHES PHASE 3 CFS CLINICAL TRIAL
Jan 26, 2004
HEMISPHERX BIOPHARMA REPORTS PUBLICATION SUGGESTING EFFICACY OF AMPLIGEN IN TREATING MYOCARDITIS VIRUS
Jan 20, 2004
HEMISPHERX BIOPHARMA ANNOUNCES JOINT WEST NILE VIRUS CLINICAL PROGRAM WITH NEW YORK HOSPITAL
Jan 13, 2004
Hemispherx Biopharma Announces Joint SARS Clinical Program with Vanderbilt University
64
65
66
67
68
69
70
71
72
73
74
<<
<
>
>>
Privacy